NCT00035035

Brief Summary

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Geographic Reach
17 countries

111 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 2, 2002

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 3, 2002

Completed
Last Updated

July 19, 2006

Status Verified

July 1, 2006

First QC Date

May 2, 2002

Last Update Submit

July 18, 2006

Conditions

Keywords

PancreasCancerUnresectable or Metastatic Cancer of the PancreasAlimta

Interventions

GEMZARDRUG
ALIMTADRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Pancreas cancer that cannot be removed by surgery OR that has spread to a new site in your body.
  • You must have one tumor that can be physically measured or scanned by the doctor.
  • You have not had any chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for pancreas cancer, including 5-FU.
  • You cannot have any radiation for 4 weeks before starting this study, and you cannot have radiation to the whole pelvis.

You may not qualify if:

  • Treatment with any medication or device that has not been approved by regulatory agencies, like the FDA, at the time you enter the study.
  • Documentation that the cancer has spread to your brain.
  • Pregnant or breastfeeding.
  • A second primary cancer.
  • Unable to stop aspirin or non-steroidal anti-inflammatory agents (like ibuprofen) for 5-8 days.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (114)

Unknown Facility

Huntsville, Alabama, United States

Location

Unknown Facility

Fountain Valley, California, United States

Location

Unknown Facility

Fullerton, California, United States

Location

Unknown Facility

Lancaster, California, United States

Location

Unknown Facility

Los Angeles, California, United States

Location

Unknown Facility

Pomona, California, United States

Location

Unknown Facility

Santa Rosa, California, United States

Location

Unknown Facility

Torrance, California, United States

Location

Unknown Facility

Fort Collins, Colorado, United States

Location

Unknown Facility

Hartford, Connecticut, United States

Location

Unknown Facility

Lake Worth, Florida, United States

Location

Unknown Facility

Miami, Florida, United States

Location

Unknown Facility

Chicago, Illinois, United States

Location

Unknown Facility

Decatur, Illinois, United States

Location

Unknown Facility

Harvey, Illinois, United States

Location

Unknown Facility

Indianapolis, Indiana, United States

Location

Unknown Facility

Wichita, Kansas, United States

Location

Unknown Facility

Crestview Hills, Kentucky, United States

Location

Unknown Facility

Louisville, Kentucky, United States

Location

Unknown Facility

Lafayette, Louisiana, United States

Location

Unknown Facility

Shreveport, Louisiana, United States

Location

Unknown Facility

Scarborough, Maine, United States

Location

Unknown Facility

Burlington, Massachusetts, United States

Location

Unknown Facility

Omaha, Nebraska, United States

Location

Unknown Facility

Albuquerque, New Mexico, United States

Location

Unknown Facility

New York, New York, United States

Location

Unknown Facility

Canton, Ohio, United States

Location

Unknown Facility

Cleveland, Ohio, United States

Location

Unknown Facility

Drexel Hill, Pennsylvania, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, United States

Location

Unknown Facility

Charleston, South Carolina, United States

Location

Unknown Facility

Columbia, South Carolina, United States

Location

Unknown Facility

Johnson City, Tennessee, United States

Location

Unknown Facility

Memphis, Tennessee, United States

Location

Unknown Facility

Nashville, Tennessee, United States

Location

Unknown Facility

San Antonio, Texas, United States

Location

Unknown Facility

Tyler, Texas, United States

Location

Unknown Facility

Tacoma, Washington, United States

Location

Unknown Facility

Marshfield, Wisconsin, United States

Location

Unknown Facility

Milwaukee, Wisconsin, United States

Location

Unknown Facility

Capitol Federal, Buenos Aires, Argentina

Location

Unknown Facility

Mendoza, Mendoza Province, Argentina

Location

Unknown Facility

Santa Fe, Rosario, Argentina

Location

Unknown Facility

Ciudad de Buenos Aires, Argentina

Location

Unknown Facility

Bankstown, New South Wales, Australia

Location

Unknown Facility

Kingswood Penrith, New South Wales, Australia

Location

Unknown Facility

Wollongong, New South Wales, Australia

Location

Unknown Facility

Southport, Queensland, Australia

Location

Unknown Facility

Fitzroy, Victoria, Australia

Location

Unknown Facility

Frankston, Victoria, Australia

Location

Unknown Facility

Innsbruck, Austria

Location

Unknown Facility

Saint Veit Glan, Austria

Location

Unknown Facility

Vienna, Austria

Location

Unknown Facility

Brussels, Belgium

Location

Unknown Facility

Ghent, Belgium

Location

Unknown Facility

Leuven, Belgium

Location

Unknown Facility

Cali, Colombia

Location

Unknown Facility

Strasbourg, Cedex, France

Location

Unknown Facility

Lille, France

Location

Unknown Facility

Marseille, France

Location

Unknown Facility

Paris, France

Location

Unknown Facility

Rennes, France

Location

Unknown Facility

Rouen, France

Location

Unknown Facility

Toulouse, France

Location

Unknown Facility

Bielefeld, Nordhein-Westfalen, Germany

Location

Unknown Facility

Berlin, Germany

Location

Unknown Facility

Bremerhaven, Germany

Location

Unknown Facility

Frankfurt, Germany

Location

Unknown Facility

Kaiserslautern, Germany

Location

Unknown Facility

Karlsruhe, Germany

Location

Unknown Facility

Magdeburg, Germany

Location

Unknown Facility

Mannheim, Germany

Location

Unknown Facility

München, Germany

Location

Unknown Facility

Neustadt/Suedharz, Germany

Location

Unknown Facility

Stuttgart, Germany

Location

Unknown Facility

Marousi, Athens, Greece

Location

Unknown Facility

Ioannina, Greece

Location

Unknown Facility

Genova, Italy

Location

Unknown Facility

Ravenna, Italy

Location

Unknown Facility

Roma, Italy

Location

Unknown Facility

Breda, Netherlands

Location

Unknown Facility

Enschede, Netherlands

Location

Unknown Facility

Roermond, Netherlands

Location

Unknown Facility

Sittard, Netherlands

Location

Unknown Facility

The Hague, Netherlands

Location

Unknown Facility

Chiclayo, Peru

Location

Unknown Facility

Lima, Peru

Location

Unknown Facility

Lisbon, Portugal

Location

Unknown Facility

Porto, Portugal

Location

Unknown Facility

Santa Maria da Feira, Portugal

Location

Unknown Facility

Santarém, Portugal

Location

Unknown Facility

Elche, Alicante, Spain

Location

Unknown Facility

Barcelona, Barcelona, Spain

Location

Unknown Facility

Madrid, Madrid, Spain

Location

Unknown Facility

Santa Cruz de Tenerife, Santa Cruz De Tenerife, Spain

Location

Unknown Facility

Zaragoza, Zaragoza, Spain

Location

Unknown Facility

Linköping, Sweden

Location

Unknown Facility

Lund, Sweden

Location

Unknown Facility

Malmo, Sweden

Location

Unknown Facility

Stockholm, Sweden

Location

Unknown Facility

Umeå, Sweden

Location

Unknown Facility

Taoyuan District, Kuei-Shan, Taiwan

Location

Unknown Facility

Yungkang City, Tainan, Taiwan

Location

Unknown Facility

Tainan, Taiwan

Location

Unknown Facility

Taipei, Taiwan

Location

Unknown Facility

Bristol, Avon, United Kingdom

Location

Unknown Facility

Hull, East Yorkshire, United Kingdom

Location

Unknown Facility

Acton, London, United Kingdom

Location

Unknown Facility

Northwood, Middlesex, United Kingdom

Location

Unknown Facility

Belfast, Northern Ireland, United Kingdom

Location

Unknown Facility

Manchester, United Kingdom

Location

Unknown Facility

Valencia, Edo. Aragua, Venezuela

Location

Unknown Facility

Estado Aragua, Maracay, Venezuela

Location

Unknown Facility

Caracas, Venezuela

Location

MeSH Terms

Conditions

Pancreatic NeoplasmsNeoplasm MetastasisNeoplasms

Interventions

GemcitabinePemetrexed

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Heterocyclic CompoundsDeoxycytidineCytidinePyrimidine NucleosidesPyrimidinesHeterocyclic Compounds, 1-RingGuanineHypoxanthinesPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingGlutamatesAmino Acids, AcidicAmino AcidsAmino Acids, Peptides, and ProteinsAmino Acids, Dicarboxylic

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

May 2, 2002

First Posted

May 3, 2002

Last Updated

July 19, 2006

Record last verified: 2006-07

Locations